The Adv Halt Trial

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Chimerix
ClinicalTrials.gov Identifier:
NCT01241344
First received: November 12, 2010
Last updated: October 31, 2013
Last verified: October 2013
  Purpose

The primary objective of this study is to evaluate the safety and efficacy of preemptive treatment with CMX001 versus placebo for the prevention of AdV disease in recipients of HSCT with asymptomatic AdV viremia.


Condition Intervention Phase
Adenovirus Disease
Drug: CMX001
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-Controlled Multi-Site Phase 2 Study Evaluation the Safety and Efficacy of Preemptive Treatment With CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation in Adults and Children

Resource links provided by NLM:


Further study details as provided by Chimerix:

Primary Outcome Measures:
  • The primary objective of this study is to evaluate the safety and efficacy of preemptive treatment with CMX001 versus placebo for the prevention of AdV disease in recipients of HSCT with asymptomatic AdV viremia [ Designated as safety issue: Yes ]

    The outcome measure for the primary endpoint will be "treatment failure". Treatment failure is a composite endpoint consisting of:

    • Progression to probable or definitive AdV disease.
    • OR increasing AdV viremia during randomized therapy (defined as increase from baseline in AdV viremia by ≥ 1 log10, confirmed on a second measurement, at least one week apart) AND requiring discontinuation from randomized therapy


Secondary Outcome Measures:
  • 1. To compare the safety and efficacy of two dosing regimens of CMX001 versus each other and versus placebo in this indication. [ Designated as safety issue: Yes ]

    2. To compare the incidence of treatment emergent dsDNA viral infections (other than those caused by AdV), in subjects treated with CMX001 QW versus CMX001 BIW versus placebo, initially, for the preemption of adenoviral disease.

    3. To characterize the safety and efficacy of CMX001 open-label therapy in patients who meet the primary endpoint of treatment failure during randomized therapy.



Enrollment: 52
Study Start Date: November 2010
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: CMX001
  • Adults: 200mg CMX001 given as four 50mg tablets orally either QW OR BIW.
  • Peds: 4mg/kg (NTE a total single dose of 200mg) given using a 5 mg/mL liquid formulation taken orally either QW OR BIW
Drug: CMX001
  • Adults: 200mg CMX001 given as four 50mg tablets orally either QW OR BIW.
  • Peds: 4mg/kg (NTE a total single dose of 200mg) given using a 5 mg/mL liquid formulation taken orally either QW OR BIW
Placebo Comparator: Placebo
  • Adults: Two matching placebo tablets taken orally QW OR BIW.
  • Peds: Matching liquid placebo taken orally QW OR BIW
Drug: CMX001
  • Adults: 200mg CMX001 given as four 50mg tablets orally either QW OR BIW.
  • Peds: 4mg/kg (NTE a total single dose of 200mg) given using a 5 mg/mL liquid formulation taken orally either QW OR BIW

  Eligibility

Ages Eligible for Study:   3 Months to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males and females ≥ 3 months and ≤ 75 years of age.
  2. Subjects have received an allogeneic HSCT.
  3. Positive serum AdV PCR (> 100 copies/mL) as measured by the central laboratory.
  4. Subject or guardian(s) are willing to comply with the protocol.
  5. Subject or guardian(s) are willing and able to understand the informed consent/assent.
  6. Females of child-bearing potential must have a negative pregnancy test (serum beta-hCG) and sexually active females must use a reliable and medically approved method of contraception throughout the study. Sexually active males of procreation potential must be able and willing to use a reliable and medically approved contraceptive method throughout the study. At least one barrier method of contraception must be used, in subjects of procreation potential.

Exclusion Criteria:

  1. Subject has possible, probable, or definitive AdV disease. See Appendix 2Error! Reference source not found. for a definition and criteria outlining possible, probable or definitive AdV disease.
  2. Suspected gut graft versus host disease (GVHD) that is not biopsy-proven (subjects with a biopsy performed may be included in the study).
  3. Subject has an eGFR ≤ 30 mL/minute and is not currently on dialysis.
  4. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 10 times the ULN, conjugated bilirubin > 5 times the upper limit of normal (ULN).
  5. Subject has mucositis preventing ingestion of oral medication.
  6. Subject is Human Immunodeficiency Virus (HIV) antibody positive, based upon available medical records.
  7. Subject has ocular hypotony, uveitis, or retinitis or any other intraocular pathology that would predispose the subject to one of these conditions.
  8. Subject has participated in any other investigational drug study or was exposed to an investigational drug within 14 days of enrollment.
  9. Is pregnant or breast-feeding or intending to conceive during the course of the study, including the follow-up period after drug discontinuation.
  10. Known immunologic hypersensitivity to CDV or CMX001 drug or any of its excipients.
  11. History of illicit drug use or alcohol abuse within the previous 6 months.
  12. Any medical condition that, in the opinion of the Investigator, might interfere with the subject's participation in the study, poses an added risk for the subject, or confounds the assessment of the subject (e.g. severe cardiovascular, central nervous system (CNS) or pulmonary disease).
  13. Subject has received CMX001, CDV, ribavirin, or leflunomide within the previous 14 days.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01241344

  Hide Study Locations
Locations
United States, Alabama
Children's Hospital of Alabama
Birmingham, Alabama, United States, 35233
United States, Arizona
Pheonix Children's Hospital
Pheonix, Arizona, United States, 85016
United States, California
City of Hope National Medical Center
Duarte, California, United States, 91010
Childrens hospital of LA
Los Angeles, California, United States, 90033
CHOC Children's Hospital
Orange, California, United States, 92868
University of California, San Francisco
San Francisco, California, United States, 94143
Lucile Packard Childrens hopsital at Stanford
Stanford, California, United States, 94304
United States, Colorado
The Children's Hospital-Denver
Aurora, Colorado, United States, 80045
United States, District of Columbia
Children's National Medical Center
Washington, District of Columbia, United States, 20010
United States, Indiana
Indiana University
Indianapolis, Indiana, United States, 46202
United States, Louisiana
LSU Health Sciences Center New Orleans Childrens Hospital
New Orleans, Louisiana, United States, 70118
United States, Massachusetts
Harvard-Children's Hospital Boston
Boston, Massachusetts, United States, 02115
United States, Minnesota
Univeristy of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, Missouri
St. Louis Children's Hosptial
St. Louis, Missouri, United States, 63110
United States, New Jersey
Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
United States, New York
Memorial Sloan Kettering
New York, New York, United States, 10021
New York Medical College
Valhalla, New York, United States, 10595
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Ohio
Cincinnati Childrens Hospital
Cincinnati, Ohio, United States, 45229
Cleveland Clinic
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
The Children's Hospital of Philadelphia
Phildadelphia, Pennsylvania, United States, 19104
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, United States, 15224
United States, Tennessee
St. Judes Children's Research Hospital
Memphis, Tennessee, United States, 38105
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
United States, Texas
UT Southwestern
Dallas, Texas, United States, 75390
Baylor College of Medicine, Texas Childrens Hospital
Houston, Texas, United States, 77030
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Methodist Hospital
San Antonio, Texas, United States, 78229
United States, Utah
Primary Children's Medical of Utah
Salt Lake City, Utah, United States, 84113
United States, Washington
Seattle Cancer Care Alliance
Seattle, Washington, United States, 98109
Sponsors and Collaborators
Chimerix
  More Information

No publications provided

Responsible Party: Chimerix
ClinicalTrials.gov Identifier: NCT01241344     History of Changes
Other Study ID Numbers: CMX001-202
Study First Received: November 12, 2010
Last Updated: October 31, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Chimerix:
Adv
Hematopoeitic Stem cell Transplant
HSCT

Additional relevant MeSH terms:
Adenoviridae Infections
DNA Virus Infections
Virus Diseases

ClinicalTrials.gov processed this record on September 18, 2014